# Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

> **NCT06657560** · PHASE1 · COMPLETED · sponsor: **Shanghai Shengdi Pharmaceutical Co., Ltd** · enrollment: 41 (actual)

## Conditions studied

- Contrast-Enhanced Magnetic Resonance Imaging Detection

## Interventions

- **DRUG:** HRS-9231

## Key facts

- **NCT ID:** NCT06657560
- **Lead sponsor:** Shanghai Shengdi Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-14
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657560, "Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06657560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*